Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cameron

Showing results (71-80 of 134) with videos related to

Pageof 14
Sort By:
BMC Cancer|April 7, 2018
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resultsLouise Hiller, Janet A Dunn, Shrushma Loi, et al.
Breast (Edinburgh, Scotland)|June 4, 2026
EBCC-15 manifesto: Removing age-related barriers to improve equity in breast cancer careFiorita Poulakaki, Etienne Brain, Icro Meattini, et al.
Breast Cancer Research and Treatment|June 4, 2011
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancerMelanie Spears, Karen J Taylor, Alison F Munro, et al.
British Journal of Cancer|June 20, 2020
Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry dataInes Mesa-Eguiagaray, Sarah H Wild, Philip S Rosenberg, et al.
International Journal of Radiation Oncology, Biology, Physics|December 27, 2011
Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long-term follow-upIan H Kunkler, Gillian R Kerr, Jeremy S Thomas, et al.
The Oncologist|May 17, 2011
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancerDavid Miles, Henri Roché, Miguel Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancerLuca Gianni, Anna Lladó, Giulia Bianchi, et al.
Breast Cancer Research : BCR|June 24, 2010
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancerKaren J Taylor, Andrew H Sims, Liang Liang, et al.
Journal of the National Cancer Institute|May 7, 2025
Response to Li, Liu, Duan et alPer Karlsson, Fyles Anthony, Bradley Arrick, et al.
BJC Reports|August 18, 2025
Hidden costs and unmet supportive care needs among individuals with experience of breast cancer and their carers in the United KingdomSzeyi Ng, Lucy S Kilburn, Hilary Stobart, et al.
Pageof 14

Showing results (71-80 of 134) with videos related to

Sort By:
Pageof 14
BMC Cancer|April 7, 2018
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resultsLouise Hiller, Janet A Dunn, Shrushma Loi, et al.
Breast (Edinburgh, Scotland)|June 4, 2026
EBCC-15 manifesto: Removing age-related barriers to improve equity in breast cancer careFiorita Poulakaki, Etienne Brain, Icro Meattini, et al.
Breast Cancer Research and Treatment|June 4, 2011
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancerMelanie Spears, Karen J Taylor, Alison F Munro, et al.
British Journal of Cancer|June 20, 2020
Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry dataInes Mesa-Eguiagaray, Sarah H Wild, Philip S Rosenberg, et al.
International Journal of Radiation Oncology, Biology, Physics|December 27, 2011
Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long-term follow-upIan H Kunkler, Gillian R Kerr, Jeremy S Thomas, et al.
The Oncologist|May 17, 2011
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancerDavid Miles, Henri Roché, Miguel Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancerLuca Gianni, Anna Lladó, Giulia Bianchi, et al.
Breast Cancer Research : BCR|June 24, 2010
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancerKaren J Taylor, Andrew H Sims, Liang Liang, et al.
Journal of the National Cancer Institute|May 7, 2025
Response to Li, Liu, Duan et alPer Karlsson, Fyles Anthony, Bradley Arrick, et al.
BJC Reports|August 18, 2025
Hidden costs and unmet supportive care needs among individuals with experience of breast cancer and their carers in the United KingdomSzeyi Ng, Lucy S Kilburn, Hilary Stobart, et al.
Pageof 14